The most striking mutational results suggested a clear division of LCNEC into ‘NSCLC-type’ and ‘SCLC-type’, a sub-classification that could be made on the basis of RB1 and/or KRAS and/or STK11/LKB1 mutation. Here, KRAS is linked to large cell neuroendocrine carcinoma.